Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-528-4
CAS number: 122-20-3
Recovery of the radioactivity from the appliances used to protect the dosing
site skin, tissues and excreta following dermal application of 19.5
mg/kg 14C-DIPA to female Fisher 344 rats.
% of applied dose
Dose site skin
Final cage wash
SD, standard deviation (n=
Protective appliance include Teﬂon patch, bandage, template
Amount of radioactivity in fat was <0.01% of the applied
Concentration of radioactivity in plasma and red blood cells (RBC) of female
Fischer 344 rats applied dermally with 19.5 mg14C-DIPA/kg
1.12 ± 0.76
0.14 ± 0.04
0.15 ± 0.10
0.31 ± 0.44
0.47 ± –a
0.04 ± 0.01
0.05 ± 0.02
0.10 ± –
0.07 ± 0.02
0.13 ± 0.04
0.14 ± 0.06
0.16 ± 0.07
0.14 ± 0.05
0.13 ± 0.07
0.14 ± –
Mean ± standard deviation (n=
collected from 2 out of 4 rats did not have suﬃcient
radio- activity to quantify.
In a combined dermal and intravenous study, the relative dermal
bioavailability (absorption), distribution, metabolism, and excretion
(ADME) of diisopropanolamine (DIPA), an alcohol amine used in a number
of industrial and personal care products, was determined.
Groups of 4 female Fischer 344 rats received either a single bolus i.v.
dose of 19.0 mg/kg 14C-DIPA in water or a dermal application of 19.5 mg/
kg 14C-DIPA in acetone to an area of 1 cm2 on the back and covered with
Time-course blood and excreta were collected and radioactivity
determined. Urine was analyzed for DIPA and monoisopropanolamine (MIPA).
Following dermal application, 20% of the dose was absorbed in 48 h with
the steady-state penetration rate of 0.2%/h. Most (14.4%) of the applied
radioactivity was excreted in urine at a relatively constant rate due to
the presence of large amount of the 14C-DIPA at the application site.
Fecal elimination was <0.2% of the dose. The absorbed DIPA did not
accumulate in tissues; only 0.1% of the administered dose was found in
liver and kidney. The absolute systemic dermal bioavailability (dose
corrected AUCdermal/AUCi.v.) of 14C-DIPA was 12%.
The ADME of DIPA contrasts that of its diethanol analogue,
diethanolamine, which displays a broad spectrum of toxicity in rats and
mice. Toxicologically signiﬁcant concentrations of DIPA are unlikely to
be achieved in the systemic circulation and/or tissues as a result of
repeated dermal application of products containing DIPA due to slow
absorption from the skin, rapid unchanged elimination in urine, and
majority of the products contain 61% DIPA.
It has to be mentioned that an overprediction of the absorption through
the skin due to several dermal applications with acetone produced a
worse-case scenario in the dermal application part presented in the
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again